Clinical Trials

Study Title:
A Phase II/III Study of N 803 (ALT 803) Plus Pembrolizumab Versus Standard of Care in Participants With Stage IV or Recurrent Non Small Cell Lung Cancer Previously Treated With Anti PD 1 or Anti PD L1 Therapy (Lung MAP Non Match Sub Study)

For more information about the trial above please contact the study team:

Principal Investigator, John Wrangle, at

Study Coordinator, Alexandra Leitner, at, or please call +1 843-792-1507.

Trial opened at the following institutions: Medical University of South Carolina